WCLC 2023 – Paul Van Schil
In this exclusive video interview Paul Van Schil, the current president-elect of the IASLC, provides insights into projects that will be at the focus of the IASLC in the near future and explains notable challenges regarding collaborative science and global education, which are part of the IASLC’s strategic plan. Furthermore, he shares his thoughts on improving accessibility to multidisciplinary care at the global level, the optimal first-line therapy for patients with pleural mesothelioma and his personal highlights from the WCLC 2023 congress.
Here is the full WCLC 2023 report.
More posts
MARS 2: no benefit of decortication in early-stage malignant mesothelioma
MARS 2: no benefit of decortication in early-stage malignant mesothelioma Surgery in th
Trop-2–directed ADCs in conjunction with immunotherapy: EVOKE-02 and TROPION-Lung04
Trop-2–directed ADCs in conjunction with immunotherapy: EVOKE-02 and TROPION-Lung04
Refining first-line regimens for extensive-stage small-cell lung cancer
Refining first-line regimens for extensive-stage small-cell lung cancer Benmels
Improved anti-EGFR strategies and other targeted innovations
Improved anti-EGFR strategies and other targeted innovations FLAURA2: first-lin
Detection and treatment of early-stage lung cancer: recent insights
Detection and treatment of early-stage lung cancer: recent insights The signifi
Preface – WCLC 2023
Preface – WCLC 2023 © private – Navneet Singh, MD DM FRCP FASCO, Professor of Pulmona
